Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- Japan Diabetes Market Grows 6.1% in FY2014: Survey
June 22, 2015
- Novartis Launches Exforge OD Tablets
June 22, 2015
- Daiichi Sankyo Initiates Multinational PIII Study of Edoxaban for Venous Thromboembolism in Cancer
June 22, 2015
- Japan to Participate in Asian PIII Trial of NC-6004 for Pancreatic Cancer: NanoCarrier
June 19, 2015
- 30 Companies Obtain Listing for Plavix Generics
June 19, 2015
- JCR, Sumitomo Dainippon Collaborate in Blood-Brain Barrier Penetration Technology for Drug Discovery
June 19, 2015
- Generic Market to Grow 9.4% in FY2015: Yano Research
June 18, 2015
- Japanese Generic Market to Reach 867.9 Billion Yen in FY2014: Survey
June 17, 2015
- Taiho Licenses Lonsurf to Servier of France for Europe
June 16, 2015
- Takeda to Submit Plans to Improve Business Operations after MHLW Order
June 15, 2015
- Lenvima More Beneficial to Patients against Sorafenib: Dr Tahara of National Cancer Center
June 15, 2015
- Carna Biosciences Licenses Its Kinase Inhibitor to Janssen Biotech of US
June 15, 2015
- Toujeo Shows Similar Glycemic Control to Lantus in PIII Study in Japanese Patients: Sanofi
June 12, 2015
- PeptiDream to Receive Milestone Payments from BMS for Designating Clinical Candidate Compound
June 12, 2015
- FY2014 Earnings of 24 Major Japanese Drug Makers: Jiho Tally
June 12, 2015
- NanoCarrier to Initiate PI Study of NC-6004 for Head, Neck Cancer in Japan
June 11, 2015
- Novartis Has High Hopes for T-Cell Therapy CTL019
June 10, 2015
- Novartis Japan Chief Vows All-Out Effort to Regain Trust
June 10, 2015
- No Difference from Clinical Trials in Incidence of Adverse Reactions to SGLT-2 Inhibitor: Prof. Kaku of Kawasaki Medical School
June 10, 2015
- R-Tech Ueno Partners with Autonomous University of Barcelona in Research for Development of VAP-1 Inhibitor
June 10, 2015
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…